Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Mitsubishi Tanabe VC Firm Certified for AMED Startup Project
Mitsubishi Tanabe Pharma said on June 16 that its US-based venture capital subsidiary has been certified under the Japan Agency for Medical Research and Development’s (AMED) project aimed to reinforce the drug discovery ecosystem in Japan. The subsidiary, MP Healthcare…
To read the full story
Related Article
- Eisai and Taiho VC Firms Certified for AMED Startup Project
November 6, 2024
- AMED Selects 6 VCs for Biotech Startup Funding Project
February 21, 2024
- 8 VC Firms Certified for AMED Funding Project to Boost Pharma Ecosystem
July 4, 2022
BUSINESS
- Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
- AstraZeneca CSO Urges Global Drug Price “Rebalancing” amid MFN Push
July 8, 2026
- JB to Build New Plant in Hokkaido to Double Ig Production
July 8, 2026
- Padcev/Keytruda Accepted for China Review in Perioperative MIBC
July 8, 2026
- Japan Ethical Drug Sales Fall 1.1% in May: Crecon
July 8, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…